CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (CAPITAL DEFICIENCY) - USD ($) $ in Thousands		Common Stock	Additional Paid-in Capital	Accumulated Deficit	Total
Beginning balance at Dec. 31, 2020		$ 35	$ 320,280	$ (347,352)	$ (27,037)
Beginning balance (in shares) at Dec. 31, 2020	[1]	34,765,280
Issuance of common stock, net of issuance cost		$ 9	37,616		37,625
Issuance of common stock, net of issuance cost (in shares)	[1]	8,749,999
Issuance of common stock under the Sales Agreement, net		$ 2	8,573		8,575
Issuance of common stock under the Sales Agreement, net (in shares)	[1]	1,867,552
Share-based compensation related to stock options			832		832
Share-based compensation related to restricted stock awards			562		562
Exercise of warrants (in shares)	[1]	173,816
Net loss for the period				(16,716)	(16,716)
Ending balance at Jun. 30, 2021		$ 46	367,863	(364,068)	3,841
Ending balance (in shares) at Jun. 30, 2021	[1]	45,556,647
Beginning balance at Mar. 31, 2021		$ 46	367,285	(352,827)	14,504
Beginning balance (in shares) at Mar. 31, 2021	[1]	45,382,831
Share-based compensation related to stock options			322		322
Share-based compensation related to restricted stock awards			256		256
Exercise of warrants (in shares)	[1]	173,816
Net loss for the period				(11,241)	(11,241)
Ending balance at Jun. 30, 2021		$ 46	367,863	(364,068)	3,841
Ending balance (in shares) at Jun. 30, 2021	[1]	45,556,647
Beginning balance at Dec. 31, 2021		$ 46	368,852	(374,934)	(6,036)
Beginning balance (in shares) at Dec. 31, 2021	[1]	45,556,647
Issuance of common stock under the Sales Agreement, net		$ 3	2,638		2,641
Issuance of common stock under the Sales Agreement, net (in shares)	[1]	2,395,823
Share-based compensation related to stock options			293		293
Share-based compensation related to restricted stock awards			831		831
Share-based compensation related to restricted stock awards (in shares)	[1]	759,482
Exercise of warrants			2		2
Exercise of warrants (in shares)	[1]	1,000
Net loss for the period				(7,620)	(7,620)
Ending balance at Jun. 30, 2022		$ 49	372,616	(382,554)	(9,889)
Ending balance (in shares) at Jun. 30, 2022	[1]	48,712,952
Beginning balance at Mar. 31, 2022		$ 46	369,688	(377,220)	(7,486)
Beginning balance (in shares) at Mar. 31, 2022	[1]	46,316,129
Issuance of common stock under the Sales Agreement, net		$ 3	2,638		2,641
Issuance of common stock under the Sales Agreement, net (in shares)	[1]	2,395,823
Share-based compensation related to stock options			144		144
Share-based compensation related to restricted stock awards			144		144
Exercise of warrants			2		2
Exercise of warrants (in shares)	[1]	1,000
Net loss for the period				(5,334)	(5,334)
Ending balance at Jun. 30, 2022		$ 49	$ 372,616	$ (382,554)	$ (9,889)
Ending balance (in shares) at Jun. 30, 2022	[1]	48,712,952

[1] Common stock, $0.001 par value; Authorized – as of June 30, 2022 and 2021 - 120,000,000 shares.